<DOC>
	<DOCNO>NCT02688387</DOCNO>
	<brief_summary>This study design understand relative bioavailability ( proportion administer dose absorbed bloodstream ) several fix dose combination ( FDCs ) tablets ambrisentan tadalafil development provide pharmacokinetic ( PK - body drug ) data enable pivotal bioequivalence ( BE - relationship two preparation drug dosage form similar bioavailability ) study . Depending formulation work , study allow 8 new FDCs compare reference ambrisentan tadalafil monotherapies . The study also evaluate 2 new formulation , may take BE study , test effect pharmacokinetics FDC feed fasted state . This single centre , Phase 1 , single dose , randomise , open label crossover study 3 study part ; study part 5 way crossover healthy subject . Part 1 study evaluate four formulation FDC ( ambrisentan 10 milligram [ mg ] + tadalafil 40 mg ) reference 2 monotherapy component take concurrently ( ambrisentan 10 mg tadalafil 40 mg ) fast state . If successful formulation identify part study , re-formulated test part 2 . If successful formulation identify part 1 study , part 2 utilized look 4 new FDC formulation . However , two formulation , less , evaluate part 2 FDC formulation may test fed fast assess food effect part 3 require . If successful formulation identify study part , 2 may test , food effect , Part 3 already assessed part . Therefore , part 3 optional utility dependent result previous study part .</brief_summary>
	<brief_title>A Phase 1 Relative Bioavailability Study Ambrisentan Tadalfil Fixed Dose Combination Tablets Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Between 18 60 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test , vital sign cardiac monitoring ( ECG 24 hour Holter ) . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator , consultation Medical Monitor require , judge document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; = 50 Kilogram ( kg ) ( 110 pound [ lbs ] ) men &gt; = 45 kg ( 99lbs ) woman body mass index ( BMI ) within range 18 30 kg per square metre ( m^2 ) ( inclusive ) Male Female . Female nonreproductive potential define , Premenopausal females one following : Documented tubal ligation Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion Hysterectomy Documented Bilateral Oophorectomy , Documented Postmenopausal define 12 month spontaneous amenorrhea Capable give sign informed consent . A blood pressure &lt; 100/55 millimetre Mercury ( mm Hg ) . Haemoglobin ( Hb ) normal range : Hb &lt; 133 ( gram per litre ) g/L male Hb &lt; 114 g/L female Alanine amino transferase ( ALT ) bilirubin &gt; 1.5 x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percentage [ % ] ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Corrected QT ( QTc ) &gt; 450 millisecond ( msec ) . The QTc QT interval correct heart rate accord Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , and/or another method , machineread manually overread . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator Medical Monitor medication interfere study procedure compromise subject safety . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram ( g ) alcohol : halfpint ( ~240 millilitre [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . Smoking 5 cigarette per week subject must able abstain smoke 24 hour period prior dose time whilst clinical unit . History sensitivity study medication , component thereof history drug allergy , opinion Investigator Medical Monitor , contraindicate participation . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result Screening within 3 month prior first dose study treatment . A positive test human immunodeficiency virus ( HIV ) antibody A positive prestudy drug/alcohol screen . Where participation study would result donation blood blood product excess 500 mL within previous 3 month The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 3 month , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Ambrisentan</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Tadalafil</keyword>
	<keyword>Fixed Dose combination</keyword>
</DOC>